Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2020 07:00 ET | Source: Aravive, Inc.

Aravive Appoints Reshma Rangwala, M.D., Ph.D., as Chief Medical Officer

HOUSTON, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced the appointment of industry...
September 08, 2020 07:00 ET | Source: Aravive, Inc.

Aravive to Participate in Upcoming Virtual Investor Conferences in September

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and...
August 27, 2020 07:00 ET | Source: Aravive, Inc.

Aravive Strengthens Leadership Team with Appointment of Key Industry Veterans

HOUSTON, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing transformative therapeutics, today announced the appointment of three...
August 03, 2020 16:01 ET | Source: Aravive, Inc.

Aravive Reports Second Quarter 2020 Financial Results and Provides Recent Corporate Updates

Successfully completed Phase 1b trial of AVB-500 in Platinum Resistant Ovarian Cancer with encouraging clinical data showing 60% ORR in the subpopulation that has not previously been treated with...
July 30, 2020 07:00 ET | Source: Aravive, Inc.

Aravive to Participate in Upcoming Virtual Investor Conferences in August

HOUSTON, July 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and...
July 23, 2020 07:00 ET | Source: Aravive, Inc.

Aravive Announces Successful Completion of Phase 1b Trial Evaluating AVB-500 in Platinum Resistant Ovarian Cancer

Identifies Recommended Phase 2 Dose for Continued Clinical Development of AVB-500 in Platinum Resistant Ovarian Cancer Aravive to Host Conference Call and Webcast Today at 8:30 a.m. ET HOUSTON, July...
June 30, 2020 16:05 ET | Source: Aravive, Inc.

Aravive Added to the Russell 2000® and Russell 3000® Indexes

HOUSTON, June 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
May 12, 2020 08:00 ET | Source: Aravive, Inc.

Aravive To Present at The 2020 RBC Capital Markets Global Healthcare Conference

HOUSTON, May 12, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
May 06, 2020 16:05 ET | Source: Aravive, Inc.

Aravive Reports First Quarter 2020 Financial Results and Provides Recent Corporate Updates

HOUSTON, May 06, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening...
April 30, 2020 08:00 ET | Source: Aravive, Inc.

Aravive and WuXi Biologics Form Strategic Collaboration to Develop Novel High-Affinity Bispecific Antibodies Targeting Cancer and Fibrosis Using the WuXiBody™ Platform

HOUSTON and SHANGHAI, April 30, 2020 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, and WuXi Biologics ("WuXi Bio") (2269.HK), a global company with...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right